10-QPeriod: Q3 FY2024

Astera Labs, Inc. Quarterly Report for Q3 Ended Sep 30, 2024

Filed November 5, 2024For Securities:ALAB

Summary

Astera Labs, Inc. (ALAB) has reported significant revenue growth in its Q3 2024 10-Q filing, with revenues increasing by 206% year-over-year for the three months ended September 30, 2024, and by 291% for the nine months ended September 30, 2024. This growth is primarily attributed to increased demand for its Aries products and a favorable product mix, including higher-selling second-generation retimers. The company also achieved a substantial improvement in gross margin, reaching 77.7% for both the three and nine-month periods, up from 76.1% and 62.5% in the prior year periods, respectively. This improvement is due to product mix, lower unit costs, and reduced inventory write-downs. Despite the strong revenue and gross profit performance, the company continues to operate at a net loss, reporting a net loss of $7.6 million for the third quarter and $108.1 million for the first nine months of 2024. This is largely driven by substantial increases in operating expenses, particularly R&D and SG&A, which saw significant jumps due to non-cash stock-based compensation expenses related to its IPO, and increased personnel costs from higher headcount. The company's cash position remains robust, bolstered by its March 2024 IPO, with cash, cash equivalents, and marketable securities totaling $886.8 million as of September 30, 2024.

Financial Highlights

47 data points
Beta

Revenue

$113.09M

77.7% Gross Margin

Net Income

-$7.59M

-6.7% Net Margin

EPS (Diluted)

$-0.05

Total Assets

$983.07M

Cash & Equivalents

$126.12M

Free Cash Flow

$46.81M

Financial Statements
Beta
Revenue$113.09M
Cost of Revenue$25.21M
Gross Profit$87.88M
R&D Expenses$50.66M
Operating Expenses$96.77M
Operating Income-$8.90M
Net Income-$7.59M
EPS (Basic)$-0.05
EPS (Diluted)$-0.05
Shares Outstanding (Basic)156.83M
Shares Outstanding (Diluted)156.83M

Key Highlights

  • 1Revenue surged by 206% YoY in Q3 2024 to $113.1 million and by 291% YoY for the first nine months to $255.2 million, driven by strong demand for Aries products and a favorable product mix.
  • 2Gross margin improved significantly to 77.7% for both Q3 and year-to-date 2024, a substantial increase from 76.1% (Q3) and 62.5% (YTD) in 2023, benefiting from product mix, lower unit costs, and reduced inventory write-downs.
  • 3Despite revenue growth, the company reported a net loss of $7.6 million in Q3 2024, bringing the year-to-date net loss to $108.1 million.
  • 4Operating expenses rose significantly, with R&D, Sales & Marketing, and G&A expenses increasing by 146%, 322%, and 479% respectively for Q3 YoY, largely due to increased stock-based compensation following the IPO and higher headcount.
  • 5The company's liquidity position is strong, with cash, cash equivalents, and marketable securities totaling $886.8 million as of September 30, 2024, following its March 2024 IPO which provided $672.2 million in net proceeds.
  • 6A material weakness in internal control over financial reporting related to risk assessment processes and IT general controls was disclosed; remediation efforts are underway.

Frequently Asked Questions

Astera Labs is experiencing substantial revenue growth driven by strong demand for its Aries products, particularly its second-generation Aries retimers which command a higher average selling price. The company also benefits from increased overall unit shipments and a favorable product mix, indicating growing adoption of its intelligent connectivity solutions in cloud and AI infrastructure.

The net loss is primarily due to significant increases in operating expenses. These increases are largely attributed to non-cash stock-based compensation expenses recognized following the company's IPO, as well as substantial investments in research and development and sales and marketing, supported by a growing headcount to scale operations.

The March 2024 IPO significantly bolstered Astera Labs' financial position. It provided net proceeds of $672.2 million, substantially increasing the company's cash, cash equivalents, and marketable securities to $886.8 million as of September 30, 2024. This improved liquidity provides the company with sufficient funding for its operations and growth initiatives for the foreseeable future.

A key challenge highlighted is the ongoing net loss despite revenue growth, driven by high operating expenses. Additionally, the company disclosed a material weakness in its internal controls over financial reporting, specifically concerning risk assessment processes and IT general controls, though remediation efforts are in progress. The company also relies on a few key customers, representing a significant portion of both revenue and accounts receivable, which introduces customer concentration risk.